ArticleJACC. Case reports2025
Carbohydrate Antigen-125: Endometrial Cancer or Heart Failure Biomarker?
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A risk prediction model for metachronous peritoneal metastasis after radical gastrectomy in gastric cancer based on peripheral blood inflammatory markers and tumor pathological features.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbohydrate antigen-125 (also known as cancer antigen-125) (CA-125) is a biomarker used to monitor for endometrial cancer progression, but it may also reflect other disease processes. CASE SUMMARY: A 70-year-old woman with metastatic endometrial cancer who was treated with paclitaxel, carboplatin, and pembrolizumab presented with new onset ascites and rising CA-125 levels concerning for cancer progression. She received a diagnosis of heart failure (HF) and normalized her CA-125 levels with loop diuretic agents without changing her oncologic treatment. DISCUSSION: CA-125 is a novel biomarker for HF monitoring because it correlates with increased intracardiac filling pressures. In this patient, concomitant endometrial malignant disease and HF complicated ascertainment of ascites and elevated biomarker origin. Therefore, clinicians should consider alternate causes of elevated CA-125 levels besides cancer progression. TAKE-HOME MESSAGE: CA-125 levels in patients with endometrial cancer may not always reflect cancer disease progression because levels can be influenced by the presence of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.